Precision BioSciences
DTIL
119 hedge funds and large institutions have $93.5M invested in Precision BioSciences in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 56 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 30
0.27% more ownership
Funds ownership: 1.71% → 1.98% (+0.27%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $96.6M → $93.5M (-$3.05M)
21% less call options, than puts
Call options by funds: $15K | Put options by funds: $19K
22% less funds holding
Funds holding: 152 → 119 (-33)
50% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.85M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$8.32M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.2M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.27M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.13M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$2.1M |
| 4 |
Goldman Sachs
New York
|
-$1.59M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.56M |
DTIL Hedge Fund Activity: Q2 2022 in Review
119 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q2 2022, worth a combined $93.5M — down 3.2% from $96.6M a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of DTIL and 28 opened new positions — a net loss of 28 holders — while 30 trimmed existing stakes and 33 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $11.3M. The largest seller was BlackRock, cutting an estimated $4.27M.
- 119 institutional investors held Precision BioSciences (DTIL) as of Q2 2022, down from 152 in Q1 2022.
- Funds reported $93.5M of Precision BioSciences stock for Q2 2022, down 3.2% quarter-over-quarter.
- 28 funds opened new Precision BioSciences positions in Q2 2022 and 56 closed out, a net change of -28 holders.
- The largest Precision BioSciences buyer in Q2 2022 was Great Point Partners, an estimated $11.3M added.
- The largest Precision BioSciences seller in Q2 2022 was BlackRock, an estimated $4.27M sold.
Based on aggregated 13F filings for Q2 2022.